Takeda Sees Portfolio As Mostly Pandemic-Resistant
But Some Trials Being Impacted
Executive Summary
Takeda says the coronavirus is affecting some of its clinical programs but that many key pipeline assets remain on track, while its existing commercial portfolio is seen as resilient by nature.
You may also be interested in...
EU Fast-Track Review In Store For Takeda’s Dengue Vaccine
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.
APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep
Join the Pink Sheet and Scrip's Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.
APAC Podcast: Virus Industry Impact, China Vaccines, Remdesivir Deals, Korea SitRep
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.